CCNE1増幅は,PKMYT1キナーゼ阻害によって合成的に致死する
David Gallo1, Jordan T F Young2, Jimmy Fourtounis2
1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Nature
|April 21, 2022
まとめ
CCNE1遺伝子を増幅すると,PKMYT1キナーゼを抑制する脆弱性が生じます. 研究者らは,ゲムシタビンと併用したCCNE1増強がんの治療に有望な抑制剤であるRP-6306を開発した.
科学分野:
- 腫瘍学
- 分子生物学
- 遺伝学
背景:
- CCNE1ロカス増幅は卵巣,子宮,胃食道がんにおいて一般的です.
- 高レベルのサイクリンEは,ゲノム不安定性と治療抵抗性に関連しています.
研究 の 目的:
- CCNE1増幅腫瘍の治療標的を特定する.
- PKMYT1キナーゼ抑制の治療の可能性を調査する.
主な方法:
- ゲノムスケールのCRISPR- Cas9合成致死性スクリーニングは,CCNE1強化細胞モデルで行われました.
- 選択的PKMYT1阻害剤であるRP-6306を開発し試験した.
主要な成果:
- CCNE1の投与量が増加すると,PKMYT1の抑制に細胞が敏感になる.
- RP- 6306は,単剤の活性とゲムシタビンによる持続的な腫瘍回帰を臨床前モデルで示した.
- RP - 6306は,CCNE1を過剰発現する細胞で選択的にCDK1を活性化させ,早期ミトーシスを引き起こした.
結論:
- PKMYT1阻害は,CCNE1増強がんに対する有望な治療戦略です.
- PKMYT1をターゲットにすることで,CCNE1増幅に関連する抵抗メカニズムを克服することができます.
さらに関連する動画
09:45Mosaic Zebrafish Transgenesis for Functional Genomic Analysis of Candidate Cooperative Genes in Tumor Pathogenesis
Published on: March 31, 2015
11.3K
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
681
関連する概念動画
Interactions Between Signaling Pathways
6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
MAPK Signaling Cascades
6.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.3K
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K
Amplifying Signals via Enzymatic Cascade
10.9K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
10.9K
cAMP-dependent Protein Kinase Pathways
6.7K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.7K
Inhibition of Cdk Activity
5.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.0K
